Mycosis fungoides – A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis

Zeev Nitsan, Nihal Kucuk, Shmuel Appel, Natalia Tichmanovich, Michael Osherov, Ron Milo

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Fingolimod was the first oral disease-modifying drug approved for the treatment of relapsing-remitting multiple sclerosis (MS). It has previously been associated with rare cases of lymphoma. Here we describe the first case of mycosis fungoides – a cutaneous lymphoproliferative disorder, in an MS patient treated with fingolimod. who developed histologically confirmed mycosis fungoides 3 years after starting fingolimod. The drug was withdrawn and the patient was treated with radiotherapy and surgical excision with remission. This report points to a possible association between fingolimod and skin lymphoproliferative disorder and emphasizes the need for periodic skin examination.

Original languageEnglish
Pages (from-to)102-103
Number of pages2
JournalJournal of Clinical Neuroscience
Volume48
DOIs
StatePublished - 1 Feb 2018

Keywords

  • Cutaneous lymphoproliferative disorder
  • Fingolimod
  • Multiple sclerosis
  • Mycosis fungoides
  • Side effects
  • Skin lymphoma

ASJC Scopus subject areas

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Fingerprint

Dive into the research topics of 'Mycosis fungoides – A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis'. Together they form a unique fingerprint.

Cite this